A new tuberculosis vaccine boosts protectiveness of the current bacille-Calmette-Guérin (BCG) vaccine, which becomes less effective over time, suggest preclinical findings from scientists at the Infectious Disease Research Institute in Seattle and Colorado State University in Fort Collins (Bertholet S et al. Sci Transl Med. 2010;2:53ra74).
The new vaccine consists of a single recombinant fusion protein produced from 4 Mycobacterium tuberculosis (Mtb) antigens from Mtb protein families associated with virulence or latency.
Hampton T. Tuberculosis Vaccine. JAMA. 2010;304(21):2350. doi:10.1001/jama.2010.1715